Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa

NCT ID: NCT03060889

Last Updated: 2017-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa to detect efficacy of Tranexamic acid in decreasing blood loss

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Previa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa

Group Type ACTIVE_COMPARATOR

Tranexamic acid

Intervention Type DRUG

10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion

Controls

Control group will not receive Tranexamic acid

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic acid

10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Term pregnancy (more than 37 weeks of gestation)
* Diagnosis of placenta previa was confirmed by ultrasound
* The patient hemoglobin percentage is more than 10 mg/dl

Exclusion Criteria

* Invading placenta previa diagnosis was confirmed by Doppler ultrasound studies
* Emergency lower segment cesarean section
* Associated medical comorbidities
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Elsayed Hassan Elbohoty

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AAbdelaziz

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

IV Tranexamic Acid Prior to Hysterectomy
NCT02911831 COMPLETED EARLY_PHASE1